Announced
Completed
Financials
Tags
United States
Pharmaceuticals
Acquisition
Domestic
Friendly
pharmaceutical
Minority
Single Bidder
Private
Completed
Synopsis
Ligand, a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, completed the acquisition of Novan, a pharmaceutical company, for $12.2m. “We remain confident in the potential of berdazimer gel to be approved, and become an important treatment for molluscum contagiosum. There are currently no FDA-approved prescription drug treatment options for this commonly acquired, highly contagious viral skin disease, and, if approved by the FDA, berdazimer gel would be the first self-application topical treatment for this indication.” Matt Korenberg, Ligand President and COO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.